Wall Street Fundamentals Releases New In-Depth Stock Reports on BLUE, CMRX, CNAT and ICEL


Follow this company

Companies Mentioned

NASDAQ:BLUE / NASDAQ:CMRX / NASDAQ:CNAT / NASDAQ:ICEL
08/26/2013 [ACCESSWIRE]

The Jumpstart Our Business Startups (JOBS) Act has been a major catalyst for the recent surge in Biotech IPOs. There have been a total of 16 U.S.-listed biotech IPOs in the first half of the year, according to data from Renaissance Capital LLC. Since the JOBS Act has been signed into law all biotech companies who have gone public have used the new pathway. "The JOBS Act provided a safe harbor under which companies could talk to investors, educate them, and get feedback about whether the company was attractive to those investors," said Kenneth Moch, CEO of Chimerix Inc. (NASDAQ: CMRX).

Bluebird bio Inc. (NASDAQ: BLUE) shares traded in the range of $25.66 to $26.79 Friday before settling to close at $26.02, an increase of 1.80 percent. The stock appears to be facing some resistance at the $27.31 and $30.58 levels with some support at $25.00. Shares of Bluebird bio have fallen approximately 3.0 percent since it became public.

More information on Bluebird bio and access to the free equity report can be found at:
www.WallStreetFundamentals.com/BLUE

Chimerix Inc. (NASDAQ: CMRX) shares traded in the range of $17.66 to $19.04 Friday before settling to close at $17.69, a decrease of 1.83 percent. The stock appears to be facing some resistance at the $19.76 and $22.49 levels. Shares of Chimerix have gained approximately 6.0 percent since it became public.

More information on Chimerix and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/CMRX

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) traded in the range of $8.95 to $9.16 Friday before settling to close at $9.09, an increase of 1.79 percent. The stock appears to be facing some resistance at the $9.72 with some support at the $8.99 and $8.25 levels. Shares of Conatus Pharmaceuticals have fallen approximately 4.0 percent since it became public.

More information on Conatus Pharmaceuticals and access to the free equity report can be found at: 
www.WallStreetFundamentals.com/CNAT

Cellular Dynamics International Inc. (NASDAQ: ICEL) shares traded in the range of $12.30 to $13.27 Friday before settling to close at $12.58, a decrease of 3.38 percent. The stock appears to be facing some resistance at $13.04. Shares of Cellular Dynamics have gained approximately 32.0 percent since it became public.

More information on Cellular Dynamics and access to the free equity report can be found at:      
www.WallStreetFundamentals.com/ICEL

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com

COMMENTS

Leave a comment...
 * 

Your Name
 *